Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
02 Mai 2024 - 3:00PM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company
dedicated to transforming the lives of patients suffering from
fluid overload, today announced that it has received a Notice of
Allowance from the U.S. Patent and Trademark Office (USPTO) for a
patent application related to its innovative pediatric Continuous
Renal Replacement Therapy (CRRT) device branded Vivian™. This
patent strengthens Nuwellis' intellectual property portfolio and
paves the way for the development of novel technology designed to
improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows
healthcare providers to switch seamlessly between stationary
operation and “transport” or “ambulation” mode, enabling
unprecedented patient mobility. This innovative feature offers
unmatched flexibility, allowing clinicians to tailor treatment
plans to the specific needs of each young patient.
"We are thrilled to receive this patent allowance from the
USPTO," said Nestor Jaramillo, Jr., President and Chief Executive
Officer of Nuwellis. “A core focus of our business strategy is
developing novel technology and a strong IP portfolio. This
innovative technology will empower healthcare providers with the
ability to adapt treatment plans as needed, ultimately leading to
improved patient care and outcomes for critically ill children and
neonates.”
Nuwellis is currently developing a new, fully integrated
pediatric continuous renal replacement therapy (CRRT) device
designed to provide care for small babies and children. This
development effort is funded in part by a $1.7 million grant from
the National Institutes of Health (NIH). The company has partnered
with Minneapolis-based research and development firm Koronis
Biomedical Technologies Corporation (KBT), the grant recipient, in
the design and development of a custom pediatric product that will
enable clinicians to better care for babies with limited kidney
function.
Nuwellis is committed to developing life-saving technologies
specifically designed for the unique needs of pediatric patients.
This patent allowance represents a significant advancement in the
company's mission to revolutionize pediatric fluid management.
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is
a medical technology company dedicated to transforming the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
commercializing the Aquadex SmartFlow® system for ultrafiltration
therapy. Nuwellis is headquartered in Minneapolis, with a wholly
owned subsidiary in Ireland. For more information visit
www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow®
SystemThe Aquadex SmartFlow system delivers
clinically proven therapy using a simple, flexible and smart method
of removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking StatementsCertain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new
market opportunities and anticipated growth in 2024 and beyond.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercialization strategy, the
impact of the COVID-19 pandemic, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. Nuwellis does not assume any obligation to
publicly update or revise any forward-looking statements, whether
due to new information, future events or otherwise.
CONTACTS
Investors:Vivian CervantesGilmartin
Groupir@nuwellis.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024